Highlights 23andMe Holding Co.

Equities

ME

US90138Q1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
0.5159 ^USD	+11.16%		+4.50%	-43.52%

Apr. 24	23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting	CI
Apr. 23	Petros, Lemonaid Health Collaborate to Expand Stendra Availability	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	CI
Petros, Lemonaid Health Collaborate to Expand Stendra Availability	Apr. 23	MT
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 18	DJ
US Equity Markets Close Mixed Thursday	Apr. 18	MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 18	MT
Sector Update: Health Care Stocks Ease in Afternoon Trading	Apr. 18	MT
Sector Update: Health Care	Apr. 18	MT
News Highlights : Top Company News of the Day - Thursday at 1 PM ET	Apr. 18	DJ
News Highlights : Top Company News of the Day - Thursday at 11 AM ET	Apr. 18	DJ
23andMe CEO Mulls Plan to Take Company Private	Apr. 18	MT
23andMe CEO Considering Taking Company Private	Apr. 18	MT
North American Morning Briefing : Stock Futures Rise After TSMC Earnings	Apr. 18	DJ
News Highlights : Top Company News of the Day - Thursday at 5 AM ET	Apr. 18	DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET	Apr. 18	DJ
23andMe CEO Wojcicki considering taking firm private, filing shows	Apr. 17	RE
23andMe Holding Co. to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research Annual Meeting 2024	Apr. 05	CI
Biggest cyberattacks in US healthcare sector	Mar. 20	RE
23andMe Holding Co. Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6	Mar. 20	CI
Earnings Flash (ME) 23ANDME Reports Q3 Revenue $44.7M, vs. Street Est of $56.3M	Feb. 07	MT
23andMe Holding Co. Provides Earnings Guidance for the Year Ending March 31, 2024	Feb. 07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

INTERVIEW - Anne Wojcicki, CEO of 23andMe: partnership with Amazon and cancer treatment results

July 13, 2023 at 02:26 pm EDT